Ampio's Pipeline Continues To Move With Another Round Of Positive Results
By VFC: Positive updates from the Ampio Pharmaceuticals' (AMPE) pipeline sparked a run to nearly ten dollars last year, before the share price started trickling back down to earth and hit lows of under four bucks in December following a round of negative articles posted on various Internet media outlets that questioned the company's practices, procedures and accuracy of reporting. Some looked at the late-year slide as a buying opportunity, given the fact that there were still multiple potential catalysts pending on the pipeline front. This week, that potential still looks to be on track as the company announced on Tuesday favorable results from the "pain score portion of the expansion phase" of the Ampion in Knee (AIK) trial which was recently completed in Australia. Preliminary analysis of the "pain scores" portion of the trial, according to Tuesday's press release, demonstrated encouraging results and suggested that Ampion might still be a therapeuticComplete Story »
- Original article
- Login or register to post comments
